Mandate

Vinge advises Precio Fishbone in connection with the sale of shares in a subsidiary company

Vinge advises Precio Fishbone AB (publ) (”Precio Fishbone”) in connection with the sale of approximately 80.1 per cent of the shares in the subsidiary Precio Fishbone Systems AB ("Omnia"), including the product Omnia Digital Workplace, to Monterro.

Omnia Digital Workplace has been awarded in several different international contexts and has for six consecutive years been ranked as the market's best SaaS product for creating a modern digital workplace.

Monterro acquires a majority stake of approximately 80.1 per cent in Omnia from Precio Fishbone while Precio Fishbone retains a minority stake of approximately 19.9 per cent. Omnia has been created through a restructuring whereby all operations and employees related to the product Omnia Digital Workplace have been transferred from Precio Fishbone to the previously wholly owned subsidiary Omnia. All shares in Omnia are transferred to a company that will be indirectly owned by Monterro and Precio Fishbone. The purchase price for the approximately 80.1 per cent of the shares in Omnia indirectly transferred to Monterro amounts to SEK 168 million. Omnia also owns Omnia Systems Ltd (Vietnam), Precio Fishbone Canada Inc, Precio Fishbone Danmark ApS and has a branch in Germany.

Vinge’s team consisted of Matthias Pannier, Gustav Persson, Maximilian Bengtsson (M&A), Dain Hård Nevonen, William Kåge (Capital Markets), Mathilda Persson (Corporate Commercial), Rebecka Målquist (Intellectual Property) and Fanny Askelöf (Transaction Support Specialist).

Related

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025